Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide information of the relative potency of prasugrel and
clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects
undergoing elective percutaneous coronary intervention (PCI).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborators:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc. The TIMI Study Group